Xiaofang Xu

Xiaofang Xu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2026 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
KCKeyu Chen
Keyu Chen
YXYufen Xu
Yufen Xu
BSBinbin Song
Binbin Song
YGYuyang Gu
Yuyang Gu
XXXiaofang Xu
Xiaofang Xu
MFMeiyu Fang
Meiyu Fang
Background: Li‐Fraumeni syndrome is a rare autosomal dominant disorder caused by a pathogenic mutation of the tumor suppressor gene TP53 . This disease starts at an early age and has been shown to be associated with multiple tumors. The study aims to discuss the clinical and genetic characteristics of Li‐Fraumeni syndrome (LFS) and to provide therapeutic experience of LFS. Materials and Methods: We conducted a retrospective analysis of the clinicopathologic features, family history, treatment and follow‐up in five LFS patients with germline TP53 (NCBI Gene: 7157 , HGNC: 11998 , OMIM: 191170 ) pathogenic/likely pathogenic (P/LP) variants. This research had been approved by the ethics committee and implemented. Results: Our study involved five LFS patients with germline TP53 P/LP variants, including thyroid cancer, ovarian melanoma, colon cancer, fibrosarcoma, and lung cancer. Among this group of patients, the age at which tumors first appeared was between 24 and 53 years old. Three patients had a family history of tumors, and the other two were probands in the family. Traditional chemotherapy has limited effectiveness in clinical practice and may increase the risk of tumor development. However, immune checkpoint inhibitors (ICIs) have shown unexpected efficacy in patients with high programmed cell death ligand‐1 (PD‐L1) expression. Next‐generation sequencing (NGS) and PD‐L1 detection may provide more potential targets for LFS patients to achieve better therapeutic outcomes. In addition, we have added a new TP53 frameshift mutation spectrum, namely c.642_643delTA (p.H214Qfs*7), which belongs to the pathogenic variant. This mutant has not been described in the existing literature. Conclusion: Patients with LFS may be potential beneficiaries of immune checkpoint inhibitors and targeted therapies.

26 September 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YGYuyang Gu
Yuyang Gu
YLYanjun Li
Yanjun Li
TQTingting Qian
Tingting Qian
XXXiaofang Xu
Xiaofang Xu
Colon adenocarcinoma (COAD) ranks among the most prevalent malignancies. C-type lectin domain family 11 member A (CLEC11A) plays a role in the initiation and progression of various cancers. However, its involvement in COAD remains unclear. This study reveals that CLEC11A expression is significantly elevated in COAD tissues compared to normal counterparts. Moreover, higher CLEC11A levels correlate with advanced T and N stages as well as pathological stage. Survival analysis further indicates that elevated CLEC11A expression is linked to poor prognosis. Cox regression analysis identifies CLEC11A as an independent prognostic factor for unfavorable survival outcomes. Additionally, increased CLEC11A expression shows a positive association with immune cell infiltration and immune checkpoint markers. CLEC11A-related differentially expressed genes (DEGs) were also identified, and functional enrichment analyses were conducted to elucidate the biological roles of CLEC11A. Unsupervised cluster analysis of these DEGs across distinct subgroups was also performed. In conclusion, CLEC11A has the potential as both a prognostic biomarker and a modulator of immune responses in COAD.